AI and machine learning reshape drug discovery for faster breakthroughs

How AI speeds up the hunt for new drugs

Artificial intelligence and machine learning are no longer just buzzwords in pharma labs. They are actively reshaping how scientists discover and develop new medicines. What once took years of trial and error in petri dishes can now happen in weeks inside a computer model.

AI algorithms can analyse massive datasets — genomic information, protein structures, and chemical libraries — to predict which molecules are most likely to work against a disease. This slashes the early discovery phase by as much as 80 percent, according to researchers at leading institutes. Several candidates born from these models have already entered human clinical trials.

From rare cancers to brain disorders

One notable example is a molecule designed by an AI platform to target a specific mutation in a rare form of lung cancer. It went from computational design to first-in-human trial in under 18 months — a process that typically takes four to six years. Another AI-discovered drug is being tested for a degenerative neurological condition that had no treatment options.

These are not isolated cases. Over a dozen AI-assisted drug candidates are now in various stages of clinical development globally. The approach is particularly promising for diseases that lack large patient populations, where traditional drug development is often financially unviable.

Cost and time savings attract big pharma

The financial incentive is enormous. Developing a single drug costs over a billion dollars on average, and nine out of ten candidates fail in trials. AI can reduce both the upfront investment and the failure rate by flagging unpromising compounds early. Major pharmaceutical companies including Pfizer, Novartis, and Roche have struck multi-million-dollar deals with AI startups.

Smaller biotech firms are also joining the race. Indian companies like Tata Consultancy Services and Wipro have launched dedicated AI drug discovery units, while academic partnerships are growing between IITs and global pharma firms. The goal is to build platforms that can design drugs from scratch for any given disease target.

Regulatory hurdles and data challenges

Regulators are catching up. The US Food and Drug Administration and the European Medicines Agency have issued draft guidance on using AI in drug development. In India, the Central Drugs Standard Control Organisation is studying how to evaluate AI-generated clinical data. Officials have not yet confirmed a timeline for formal guidelines.

Data quality remains a bottleneck. AI models are only as good as the data they are trained on. Incomplete or biased datasets can produce misleading predictions. Scientists also caution that AI cannot yet replicate the nuanced judgment of experienced pharmacologists, especially when dealing with complex, multi-target diseases.

What comes next

Experts expect the first fully AI-discovered drug to receive regulatory approval within the next two to three years. If successful, it will open the floodgates for a new generation of therapies — faster, cheaper, and targeted at conditions that have long defied conventional science.